# US 12,594,338 B2 · Cisplatin analogue with potent anti-cancer effects and synthesis thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,338 B2
- Document ID: US12594338B2
- Status: Granted
- Kind: B2
- Application number: 18/227,094
- Filed: 2023-07-27
- Published: 2024-02-08
- Granted: 2026-04-07
- Earliest claimed: 2022-07-29
- Assignees: King Faisal Specialist Hospital & Research Centre
- Applicants: King Faisal Specialist Hospital & Research Centre
- Inventors: Abdelilah Aboussekhra; Ibrahim Al-Jammaz; Basem Al-Otaibi; Noura N. Alraouji
- Web page: https://patentgrep.com/patent/US12594338B2

## CPC

- A61K 47/54: the modifying agent being an organic compound
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07F 15/0093: {without a metal-carbon linkage}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to a compound comprising a cisplatin component and a eugenol component. The present invention further relates to a synthesis method of said compound, pharmaceutical compositions comprising the compound and its medical uses. The present invention further relates to a method of treatment of cancer.

## Claims

### Claim 1

A compound comprising a cis-diamminedichloroplatinum II component (cisplatin component) covalently connected to a 2-methoxy-4-(prop-2-en-1-yl)phenol component (eugenol component).

### Claim 2 (depends on 1)

A pharmaceutical composition comprising:
(a) a compound of claim 1; and
(b) optionally, a pharmaceutically acceptable excipient(s) or carrier.